Celltrion to invest 1.2 tln won in S. Korea to meet rising demand | Yonhap News Agency

## Summary
OK SEOUL, March 24 (Yonhap) -- Celltrion Inc., a major biopharmaceutical company, said Tuesday it will invest 1.2 trillion won (US$805.6 million) in South Korea to expand production facilities, with additional investment planned overseas, to meet rising global demand. As a first step, Celltrion will invest 1.2 trillion won in expanding the fourth and fifth plants at its Songdo campus, adding a combined capacity of 180,000 liters. This undated photo from Yonhap News TV shows Celltrion Inc.'s corporate image. (PHOTO NOT FOR SALE) (Yonhap) To further strengthen its competitiveness in the United States, Celltrion has also finalized plans to expand production facilities in Branchburg, New Jersey, increasing drug substance capacity by 75,000 liters to 141,000 liters from the previously planned 66,000-liter increase. This photo, provided by Celltrion Inc., shows its research and development center in Incheon, west of Seoul. (PHOTO NOT FOR SALE) (Yonhap) brk@yna.co.kr (END) Related Articles Celltrion wins 294.9 bln-won drug substance supply deal from global firm (LEAD) Celltrion's Q4 net more than doubles on expanded biosimilar lineup (LEAD) Celltrion completes acquisition of U.S. biopharmaceutical plant Celltrion to invest 4 tln won to expand domestic facilities Keywords #Celltrion #drug Articles with issue keywords Most Liked Netflix, BTS to turn Seoul into world's 'biggest watch party' Four decades of Damien Hirst on display at MMCA, from shark to cherry blossoms (LEAD) FM Cho sidesteps questions on whether U.S. asked Seoul to send warships to Middle East 'BTS: The Return' captures brotherhood under 'heavy crown': director (3rd LD) About 40,000 fans gather for BTS comeback concert in downtown Seoul Most Saved Netflix, BTS to turn Seoul into world's 'biggest watch party' (LEAD) FM Cho sidesteps questions on whether U.S. asked Seoul to send warships to Middle East Four decades of Damien Hirst on display at MMCA, from shark to cherry blossoms Korean Pavilion at Venice Biennale seeks comfort through art, with Han Kang's sculpture of blackened trees 'BTS: The Return' captures brotherhood under 'heavy crown': director Most Viewed All Categories (LEAD) Lee stresses self-reliant defense, citing 'very complex' global situation U.S. soldier booked for assaulting S.

## Article Content
Facebook
X
More
Pinterest
Linked in
Tumblr
Reddit
Facebook Messenger
Copy URL
URL is copied.
OK
SEOUL, March 24 (Yonhap) -- Celltrion Inc., a major biopharmaceutical company, said Tuesday it will invest 1.2 trillion won (US$805.6 million) in South Korea to expand production facilities, with additional investment planned overseas, to meet rising global demand.
The investment plan is part of Celltrion's mid- to long-term business strategy aimed at securing stable production and supply of next-generation biosimilars and new drugs, and preparing for its contract manufacturing organization (CMO) business.
The infrastructure expansion will be carried out in phases through 2030 at its Songdo facilities in Incheon, west of Seoul, as well as at overseas production hubs.
As a first step, Celltrion will invest 1.2 trillion won in expanding the fourth and fifth plants at its Songdo campus, adding a combined capacity of 180,000 liters.
The expansion is aimed at supporting growing production demand for the company's pipeline while responding to increasing CMO orders.
This undated photo from Yonhap News TV shows Celltrion Inc.'s corporate image. (PHOTO NOT FOR SALE) (Yonhap)
To further strengthen its competitiveness in the United States, Celltrion has also finalized plans to expand production facilities in Branchburg, New Jersey, increasing drug substance capacity by 75,000 liters to 141,000 liters from the previously planned 66,000-liter increase.
With rising demand for biopharmaceutical products in the United States, Celltrion's Branchburg facilities are expected to support the supply of products and the company's CMO business.
Upon completion, Celltrion said its total drug substance production capacity will increase to 571,000 liters from 316,000 liters.
The company said it aims to achieve 100 percent in-house drug substance production, which is expected to improve cost efficiency.
Celltrion added it will also place greater focus on drug product manufacturing to enhance end-to-end production competitiveness.
A new drug product facility at the Songdo campus is scheduled for completion within this year, with commercial production set to begin next year.
The new plant will have an annual capacity of 6.5 million vials, bringing the company's total capacity to 105 million vials per year.
"This investment will enable the company to respond swiftly to growing global demand for biologics while significantly improving profitability through strengthened cost competitiveness and supply stability," a Celltrion official said.
This photo, provided by Celltrion Inc., shows its research and development center in Incheon, west of Seoul. (PHOTO NOT FOR SALE) (Yonhap)
brk@yna.co.kr
(END)
Related Articles
Celltrion wins 294.9 bln-won drug substance supply deal from global firm
(LEAD) Celltrion's Q4 net more than doubles on expanded biosimilar lineup
(LEAD) Celltrion completes acquisition of U.S. biopharmaceutical plant
Celltrion to invest 4 tln won to expand domestic facilities
Keywords
#Celltrion
#drug
Articles with issue keywords
Most Liked
Netflix, BTS to turn Seoul into world's 'biggest watch party'
Four decades of Damien Hirst on display at MMCA, from shark to cherry blossoms
(LEAD) FM Cho sidesteps questions on whether U.S. asked Seoul to send warships to Middle East
'BTS: The Return' captures brotherhood under 'heavy crown': director
(3rd LD) About 40,000 fans gather for BTS comeback concert in downtown Seoul
Most Saved
Netflix, BTS to turn Seoul into world's 'biggest watch party'
(LEAD) FM Cho sidesteps questions on whether U.S. asked Seoul to send warships to Middle East
Four decades of Damien Hirst on display at MMCA, from shark to cherry blossoms
Korean Pavilion at Venice Biennale seeks comfort through art, with Han Kang's sculpture of blackened trees
'BTS: The Return' captures brotherhood under 'heavy crown': director
Most Viewed
All Categories
(LEAD) Lee stresses self-reliant defense, citing 'very complex' global situation
U.S. soldier booked for assaulting S. Korean man at club
25 pct of N. Korean defectors from near Punggye-ri nuclear test site show chromosome mutations: data
(LEAD) N. Korea's Kim reappointed as president of state affairs
N. Korean leader's sister rejects Japan's summit proposal
Most Viewed More
Most Viewed Photos
N. Korea's Kim reappointed as president of state affairs
Cherry blossoms on Jeju Island
N. Korea's Kim reappointed as president of state affairs
N. Korea's Kim reappointed as president of state affairs
prev
Celltrion to invest 1.2 tln won in S. Korea to meet rising demand
Next
Celltrion to invest 1.2 tln won in S. Korea to meet rising demand

---

## Expert Analysis

### Merits
N/A

### Areas for Consideration
- This photo, provided by Celltrion Inc., shows its research and development center in Incheon, west of Seoul. (PHOTO NOT FOR SALE) (Yonhap) brk@yna.co.kr (END) Related Articles Celltrion wins 294.9 bln-won drug substance supply deal from global firm (LEAD) Celltrion's Q4 net more than doubles on expanded biosimilar lineup (LEAD) Celltrion completes acquisition of U.S. biopharmaceutical plant Celltrion to invest 4 tln won to expand domestic facilities Keywords #Celltrion #drug Articles with issue keywords Most Liked Netflix, BTS to turn Seoul into world's 'biggest watch party' Four decades of Damien Hirst on display at MMCA, from shark to cherry blossoms (LEAD) FM Cho sidesteps questions on whether U.S. asked Seoul to send warships to Middle East 'BTS: The Return' captures brotherhood under 'heavy crown': director (3rd LD) About 40,000 fans gather for BTS comeback concert in downtown Seoul Most Saved Netflix, BTS to turn Seoul into world's 'biggest watch party' (LEAD) FM Cho sidesteps questions on whether U.S. asked Seoul to send warships to Middle East Four decades of Damien Hirst on display at MMCA, from shark to cherry blossoms Korean Pavilion at Venice Biennale seeks comfort through art, with Han Kang's sculpture of blackened trees 'BTS: The Return' captures brotherhood under 'heavy crown': director Most Viewed All Categories (LEAD) Lee stresses self-reliant defense, citing 'very complex' global situation U.S. soldier booked for assaulting S.

### Implications
- OK SEOUL, March 24 (Yonhap) -- Celltrion Inc., a major biopharmaceutical company, said Tuesday it will invest 1.2 trillion won (US$805.6 million) in South Korea to expand production facilities, with additional investment planned overseas, to meet rising global demand.
- The infrastructure expansion will be carried out in phases through 2030 at its Songdo facilities in Incheon, west of Seoul, as well as at overseas production hubs.
- As a first step, Celltrion will invest 1.2 trillion won in expanding the fourth and fifth plants at its Songdo campus, adding a combined capacity of 180,000 liters.
- Upon completion, Celltrion said its total drug substance production capacity will increase to 571,000 liters from 316,000 liters.

### Expert Commentary
This article covers celltrion, production, seoul topics. Areas of concern are also raised. Readability: Flesch-Kincaid grade 0.0. Word count: 703.